more

Kezar Life Sciences (KZR)

(Delayed Data from NSDQ)

$0.80 USD

+0.01 (1.89%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.80 0.00 (-0.61%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research Published on October 04,2023

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?

by Zacks Equity Research Published on July 18,2022

The mean of analysts' price targets for Kezar Life Sciences, Inc. (KZR) points to an 81.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KZRPositive Net Change

Biotech ETF Tops in June: 5 Stocks That Outperform

by Sweta Killa Published on June 30,2022

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet

by Zacks Equity Research Published on June 30,2022

The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

KZRPositive Net Change

Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

by Zacks Equity Research Published on June 29,2022

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

Kezar (KZR) Doubles on Promising Kidney Disorder Study Data

by Zacks Equity Research Published on June 28,2022

Shares of Kezar (KZR) surge more than 100% during after-hour trading on Jun 27, following a promising data readout from a mid-stage study evaluating zetomipzomib in patients with active lupus nephritis.

biotechs

Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a Turnaround

by Zacks Equity Research Published on June 10,2022

Kezar Life Sciences, Inc. (KZR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

KZRPositive Net Change

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

by Zacks Equity Research Published on June 03,2022

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

by Zacks Equity Research Published on May 31,2022

Style Box ETF report for CSML

Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research Published on May 23,2022

Kezar Life Sciences, Inc. (KZR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

KZRPositive Net Change

After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR)

by Zacks Equity Research Published on May 23,2022

The heavy selling pressure might have exhausted for Kezar Life Sciences, Inc. (KZR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.